New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Pfizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended survival in certain patients with muscle-invasive bladder cancer (MIBC). The ...

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...